Clinical trials: Efficacy of Hemostatic Agents
Multiple Myeloma, Carfilzomib
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
This study is a prospective, single center, single arm phase II clinical trial. The study population consists of patients who have received treatment with VRd or VRd lite regimens for 2-8 courses in the past and have achieved…
- Conditions
- Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
- Trial name
- DKPD (NCT07015021)
- Testing
- Daratumumab, Cafizomide, Pomalidomide
- Volunteers
- 72 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT07863609
- Testing
- TX002100
- Volunteers
- 20 people
- Sponsor
- Tectonic Operating Company, Inc.
Relapsed/ Refractory Multiple Myeloma
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
- Trial name
- NCT03445663
- Testing
- AMG 424
- Where
- 8 sites in United States, Australia
- Volunteers
- 27 people
- Sponsor
- Xencor, Inc.
Multiple Myeloma
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.
- Trial name
- NCT00087867
- Testing
- SCIO-469, SCIO-469 and bortezomib
- Volunteers
- 62 people
- Sponsor
- Scios, Inc.
Multiple Myeloma
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
This study aims to assess the efficacy and safety of pomalidomide in combination with low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.
- Trial name
- NCT02916420
- Testing
- Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Multiple Myeloma
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma.
- Trial name
- NCT04003168
- Testing
- Human BCMA targeted T Cells Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma, Renal Failure
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment
Multiple myeloma (MM) is a malignant plasma cell disorder, characterized by the presence of more than 10 % of clonal plasma cells in the bone marrow.
- Trial name
- IRMYG (NCT03234335)
- Testing
- Data collection
- Where
- 33 sites in Algeria, Belgium and 2 more
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Multiple Myeloma
ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
This is a Phase Ib/II safety and efficacy trial of single agent ABC294640, an inhibitor of sphingosine kinase 2 and dihydroceramide desaturase, in refractory or relapsed multiple myeloma (MM).
- Trial name
- ABC-103 (NCT02757326)
- Testing
- Opaganib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- RedHill Biopharma Limited
Waldenström's Macroglobulinemia
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
- Trial name
- ASPEN (NCT03053440)
- Testing
- BGB-3111, Ibrutinib
- Where
- 58 sites in United States, Australia and 10 more
- Volunteers
- 201 people
- Sponsor
- BeiGene
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
Neoplasms, Plasma Cell, Neoplasms by Histologic Type
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple…
- Conditions
- Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders
- Trial name
- NCT06271252
- Testing
- OriCAR-017
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- OriCell Therapeutics Co., Ltd.
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Multiple Myeloma
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM.
- Trial name
- NCT05594797
- Testing
- Human BCMA Targeted T Cells Injection
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The objective of this study is to evaluate the efficacy and safety of Velcade plus dexamethasone used as induction chemotherapy prior to autologous transplantation.
- Trial name
- NCT00337506
- Testing
- Dexamethasone, velcade
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma (MM)
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
- Trial name
- NCT04649073
- Testing
- OPC-415
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Multiple Myeloma
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
A multicenter, double arms, prospective randomized controlled phase 4 study. Approximately 50 previously untreated subjects with multiple myeloma will be enrolled.
- Trial name
- NCT01868828
- Testing
- PAD, VCD, ASCT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
Rationale: We recently reported a study where overall and event free survivals in newly diagnosed myeloma patients receiving an autologous transplant followed by an allograft from an HLA-identical sibling were superior as…
- Trial name
- NCT01264315
- Testing
- Lenalidomide
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma, Relapsed/Refractory
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma
- Trial name
- NCT06581640
- Testing
- CAR-T treatment
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Colonic Polyps
The Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet)
The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic…
- Trial name
- NCT05737017
- Testing
- ClearCoajet
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Seoul St. Mary's Hospital
Lymphoma, Non-Hodgkin, Hodgkin Disease
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma
- Trial name
- TXA127-PBSC (NCT01121120)
- Testing
- TXA127
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Tarix Pharmaceuticals